VGS is a revenue stage company located in Tel Aviv, Israel. VGS developed novel external scaffolds for the treatment of the Achilles hill of peripheral and heart bypass surgeries (CABG) – vein graft disease. The company’s products are commercialized in several European markets and used routinely in leading heart and vascular centers. IDE approval to commence pivotal study with VEST (external scaffold for CABG) was granted in 2016 and FDA approval is expected in 2019.

http://www.graftsolutions.com/